2004: Rofecoxib (Vioxx) Cardiovascular Risk Withdrawal (2004)
On 30 September 2004, Merck voluntarily withdrew rofecoxib (Vioxx) from markets worldwide—at that
time the largest prescription drug withdrawal in history. Rofecoxib had been approved in 1999 as a
selective COX-2 inhibitor intended to provide the anti-inflammatory and analgesic benefits of
traditional NSAIDs while sparing COX-1-mediated gastric protection, thereby reducing gastrointestinal
bleeding risk. It became one of the fastest-selling drugs ever, with annual sales exceeding $2.5 billion
and an estimated 80 million patients having received the drug globally.
The safety signal emerged from the APPROVe (Adenomatous Polyp Prevention on Vioxx) trial, designed
to test rofecoxib for colorectal cancer prevention. An interim analysis revealed an approximately
doubled risk of serious cardiovascular events—myocardial infarction and stroke—in the rofecoxib
arm compared with placebo, beginning 18 months after treatment initiation. The proposed mechanism
centred on imbalanced prostanoid inhibition: COX-2 selective drugs suppressed prostacyclin (PGI₂,
an antiplatelet and vasodilatory prostanoid predominantly synthesised via COX-2 in endothelium)
without affecting thromboxane A2 production (which requires COX-1 in platelets), thereby tipping
the haemostatic balance toward thrombosis.
Subsequent analyses of the VIGOR trial data—which had compared rofecoxib with naproxen in
rheumatoid arthritis and shown a fivefold excess of myocardial infarctions in 2000—raised questions
about whether Merck had identified the cardiovascular signal years before withdrawal and failed to
respond adequately. The episode triggered congressional investigations, multiple class-action
lawsuits ultimately settled for billions of dollars, and fundamental reforms in FDA post-market
surveillance, risk communication, and the role of advisory committees.
The Vioxx case became the paradigmatic example of how mechanistic plausibility—COX-2 selectivity
should protect the gut—can mask adverse drug effects that emerge only in large, long-term exposed
populations.
لماذا كان لهذا أهمية
The rofecoxib withdrawal reshaped pharmacovigilance globally, prompting mandatory post-marketing
commitments, expanded use of FDA's Sentinel System for real-world safety monitoring, and more
stringent cardiovascular risk evaluation for all analgesic and anti-inflammatory drugs. It stands
as a canonical case study in the limitations of mechanistic reasoning as a substitute for long-term
safety data in large populations.